Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and MEDI0457 for HPV16+ Oropharynx Cancer
NCT04001413Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MEDI0457 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Sep 2019; status: withdrawn.
02
Drugs
MEDI0457
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT04001413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001413.